OPNT Opiant Pharmaceuticals Inc

Lightlake Therapeutics Inc. (OTCBB: LLTP), a drug discovery company developing innovative solutions to combat the worldwide epidemic in obesity – a trillion dollar market - has appointed Dr Roger Crystal as CEO.

Crystal, 33, will spearhead Lightlake’s operations from its London HQ, overseeing the clinical trials programme and the bringing to market of a groundbreaking safe and effective treatment for obesity and unhealthy eating habits.

He began his career as a medical doctor in 2002 and qualified as a surgeon in 2005, most recently at St Mary’s Hospital, London. He has an MBA awarded by the London Business School.

Whilst on the MBA Dr Crystal’s experience also included internship at investment bank Goldman Sachs International and he was President of the Healthcare Club at London Business School, from where he has a valuable network. As Lightlake CEO, he will continue to work in healthcare strategy management consulting.

“We are proud to announce the appointment of Dr Crystal. We wanted an individual with clinical, financial and business experience.” said a Lightlake spokesperson.

“Dr Crystal has that rare combination of treating people up close and personal while having the business acumen to drive our product to market quickly, efficiently and with efficacy. Unhealthy eating is costing nations billions in addition to the social costs to individuals and families, ranging from depression to diabetes. Lightlake believes the clinical trials beginning in January will prove its product will be a fast, effective and – unlike other pharmaceutical products – a safe solution free of side effects, to one of the biggest health crises of our time.”

This press release contains forward-looking information within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. For those statements, the Company claims the protection of the safe harbor for forward-looking statements provisions contained in the Private Securities Litigation Reform Act of 1995 and any amendments thereto. Such forward-looking statements by definition involve risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. In particular, there is no assurance that production, pricing levels or other factors pertaining to the manufacturing and retail operations will be sustained at the expected rates or levels over time. Discussions of factors, which may affect future results, are contained in the Company's most recent SEC filings.

Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024